Pharma commercial intelligence, news & analysis

Evaluate radically transforms your confidence in strategic portfolio decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

How we can help you

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview.

OUR PRODUCTS

EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the only single view of the risk and return of the R&D landscape from EvaluatePharma Vision.

OUR SERVICES

Custom Solutions

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

December 12, 2019

Ash 2019 winners and losers

Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.

December 12, 2019

SABCS 2019 – Tecentriq stumbles in triple negative disease

Disappointing data in a small neoadjuvant trial testing Tecentriq in triple negative breast cancer suggests that once again Keytruda may have an edge.

December 11, 2019

SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance

December 10, 2019

Ash 2019 – Regeneron takes the bispecific baton and runs